In the ORIGIN trial, which enrolled 12,537 patients with CV risk factors and impaired fasting glucose, glucose tolerance, or T2DM, subjects were randomly assigned to receive insulin or standard care. The gene discussed is INS; the disease is type 2 diabetes mellitus.